WilmerHale client, The Medicines Company, announced yesterday that it had completed its acquisition of Targanta Therapeutics Corporation.
The Medicines Company completed the transaction through a cash tender offer followed by a short form merger. The Medicines Company paid Targanta stockholders $2.00 per share, net to the seller in cash, plus the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.
With the consummation of the acquisition, Targanta has become a wholly owned subsidiary of The Medicines Company. Further details can be found by clicking here.
WilmerHale was legal advisor to The Medicines Company in this transaction, with a team including: partners David Redlick, Hal Leibowitz, Stuart Falber and Jeffrey Hermanson; counsels Marisa Murtagh and Jessica Lopez; and associates Dana Krueger and Erica Koenig.